LP-284
DNA Damage Repair (DDR) Deficient Cancers; Soft Tissue Sarcoma
Phase 1Active (Orphan Drug Designation for Sarcoma)
Key Facts
Indication
DNA Damage Repair (DDR) Deficient Cancers; Soft Tissue Sarcoma
Phase
Phase 1
Status
Active (Orphan Drug Designation for Sarcoma)
Company
About Lantern Pharma
Lantern Pharma is an emerging, oncology-focused biopharmaceutical company at the intersection of artificial intelligence, genomics, and machine learning. Its core asset is the RADR® platform, which leverages approximately 200 billion oncology-focused data points and over 200 ML algorithms to de-risk and accelerate drug development. The company's mission is to deliver targeted therapies to the right cancer patients, with a current portfolio spanning three lead drug candidates and an ADC program across 12 cancer indications.
View full company profile